Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 13,266 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Adult Disease Clear all

Conditions: Erythropoietic Protoporphyria (EPP), X-Linked Porphyria (XLP)
Interventions: Not listed
Lead sponsor: Portal Therapeutics, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: Boston, Massachusetts • New York, New York • Wake Forest, North Carolina + 2 more

Conditions: Obese Individuals, Central Adiposity
Interventions: Beetroot Juice - Active + Exercise, Beetroot juice placebo + Exercise, Beetroot Juice - Active + No exercise, Beetroot juice placebo+ No exercise; Dietary Supplement
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 40 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Aphakia, Postcataract
Interventions: KI-362-US1 (YP2.2VM); Device
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 9
States / cities: Beverly Hills, California • Grand Junction, Colorado • Gainesville, Georgia + 5 more

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ, Biliary Tract Cancer (BTC), Esophageal Squamous Cell Carcinoma (ESCC), Ovarian Cancer, Endometrial Cancer, Cervical Cancer Metastatic, Non-small Cell Lung Cancer (NSCLC)
Interventions: CR-002; Drug
Lead sponsor: Crescent Biopharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Austin, Texas • Dallas, Texas • Fairfax, Virginia

Conditions: Sleep Wake Disorders, Sleep Disorders, Circadian Rhythm, Sleep Disorders, Intrinsic, Advanced Sleep Phase Syndrome (ASPS), Advanced Sleep Phase Syndrome, Advanced Sleep Phase, Delayed Sleep Phase, Delayed Sleep Phase Syndrome, Non-24 Hour Sleep-Wake Disorder, Irregular Sleep-Wake Syndrome, Shift-Work Sleep Disorder, Shift Work Type Circadian Rhythm Sleep Disorder, Delayed Phase Sleep Syndrome
Interventions: sleep-wake timing, constant routine; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Recurrent Adult Hodgkin Lymphoma
Interventions: basiliximab, carmustine, etoposide, cytarabine, melphalan, pharmacological study, laboratory biomarker analysis, autologous hematopoietic stem cell transplantation, yttrium Y 90-labeled basiliximab; Biological · Drug · Other + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 1
States / cities: Duarte, California

Conditions: Generalized Anxiety Disorder
Interventions: Placebo, DT120; Other · Drug
Lead sponsor: Definium Therapeutics US, Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 34
States / cities: Gilbert, Arizona • Scottsdale, Arizona • La Jolla, California + 27 more

Conditions: Obesity
Interventions: Biometric-informed care, Control Arm: Standard Care; Behavioral
Lead sponsor: Jeff Reeves; Other
Eligibility: 18 Years to 64 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: San Diego, California

Conditions: Hepatic Insufficiency, Neoplasms
Interventions: Onureg; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Iowa City, Iowa • Detroit, Michigan • Cleveland, Ohio + 1 more

Conditions: Nicotine Dependence, Tobacco Use Disorder
Interventions: Varenicline Pill, Contingency management, Counseling; Drug · Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 40 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Charleston, South Carolina • Lancaster, South Carolina • Pickens, South Carolina

Conditions: Adult Lymphoblastic Lymphoma
Interventions: Fludarabine, Total Body Irradiation; Drug · Procedure
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 40 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: BCT197, Placebo; Drug
Lead sponsor: Mereo BioPharma; Industry
Eligibility: 40 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Michigan City, Indiana • Baltimore, Maryland • Milwaukee, Wisconsin

Conditions: Vitiligo
Interventions: Upadacitinib, Placebo, NB-UVB (narrow-band ultraviolet B) Phototherapy; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years and older
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 46
States / cities: Glendale, Arizona • Phoenix, Arizona • Encino, California + 35 more

Conditions: Glabellar Lines
Interventions: OnabotulinumtoxinA X, Placebo; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 18
States / cities: Glendale, Arizona • Los Angeles, California • Newport Beach, California + 15 more

Conditions: Metabolic Associated-dysfunction Steatotic Liver Disease (MASLD), Metabolic Associated-dysfunction Steatohepatitis (MASH)
Interventions: Standard of care acceptance-based behavioral weight loss program, Occupational therapy dietary and lifestyle modifications; Behavioral
Lead sponsor: Grand Valley State University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Wyoming, Michigan

Conditions: Brain and Central Nervous System Tumors
Interventions: erlotinib hydrochloride; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Type 1 Diabetes
Interventions: Sleep-Opt, Healthy Living; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Anaemia
Interventions: Daprodustat (GSK1278863); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Interventions: BIIB059 (litifilimab); Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 13
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 10 more

Conditions: Nicotine Dependence
Interventions: Tailored treatment, Standard Treatment; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Myofascial Pain, Myalgia
Interventions: Brief Behavioral Therapy for Insomnia, BBTI, Physical Self-Regulation, PSR; Behavioral
Lead sponsor: Ian Boggero, PhD; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Pathogen Resistance, Pneumococcal Infection, Pneumonia
Interventions: Colistimethate sodium; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: Baltimore, Maryland • Cleveland, Ohio

Conditions: Non-alcoholic Fatty Liver Disease
Interventions: GSK4532990; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 14
States / cities: Chula Vista, California • Montclair, California • San Diego, California + 8 more

Conditions: Relapsed B-Cell Acute Lymphoblastic Leukemia
Interventions: leukapheresis or collection of PBMCs, cyclophosphamide based chemotherapy regimens, modified T cells; Procedure · Drug · Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 26 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Search by objective public record fields.

Observational Study of Adults and Adolescents With Erythropoietic Protoporphyria (EPP) and X-linked Porphyria (XLP)

Post-exercise Blood Pressure With Inorganic Nitrate

Trial to Investigate the Safety and Effectiveness of the KI-362-US1 (YP2.2VM) Intraocular Lens (IOL) in Adult Participants for Correction of Aphakia Following Cataract Extraction

CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

Biomarkers for Circadian Timing in Healthy Adults

Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma

A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)

Continuous Wearable Biometric Monitoring in Adults Undergoing Obesity Treatment (SMART-BMI)

A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies

E-cigarette Cessation in Adults Who Co-use Cannabis

Fludarabine / Total Body Irradiation Regimen for ALLO HCT in Acute Lymphoblastic Leukemia

Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease

A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines

Behavioral Lifestyle Intervention for Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Adults

Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme

Sleep Optimization to Improve Glycemic Control in Adults With Type 1 Diabetes

Daprodustat Hepatic Impairment Study

A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

A Smoking Cessation Treatment for Adult Women

BBTI vs PSR in Musculoskeletal Orofacial Pain Adults

Aerosolized and Intravenous Colistin in Healthy Adults

Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH

T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia